Ingredient of human breast milk may be a new treatment for warts

New Swedish research suggests that HAMLET or "Human-lactalbumin made lethal to tumor cells" an ingredient of human breast milk may be a new treatment for warts.

The research looked at the effect of HAMLET on skin papillomas and whether alpha lactalbumin–oleic acid a compound found in breast milk killed wart cells. The study has been published in this week's issue of the New England Journal of Medicine.

A wart is a generally small, rough, cauliflower-like growth, typically on hands and feet. Warts are common and contagious, caused by a viral infection with one of the Papilloma virus strains. They typically disappear after a few months but, if untreated, can last for years and can recur. A few Papilloma viruses are known to cause cancer.

Current treatments for warts include:

  • Freezing and surgically removing the infected spot
  • Treatment with chemical compounds, usually salicylic acid
  • Laser treatment

The study involved 40 patients with cutaneous papillomas that were resistant to conventional treatment. The results of the first phase showed that three weeks of treatment reduced the size of warts by at least 75% in all 20 volunteers.

83% of the 40 volunteers had no warts after 2 years.

The Lund University team concluded that treatment with topical alpha lactalbumin–oleic acid has a beneficial and lasting effect on skin papillomas. They also hope their research may lead to new treatments for common warts as well as cervical cancer and genital warts.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Overtreatment of older men with prostate cancer raises concerns